Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Abstract Text:

Nicola J Camp,Lisa A Cannon-Albright,James M Farnham,Agnes B Baffoe-Bonnie,Asha George,Isaac Powell,Joan E Bailey-Wilson,John D Carpten,Graham G Giles,John L Hopper,Gianluca Severi,Dallas R English,William D Foulkes,Lovise Maehle,Pal Moller,Ros Eeles,Douglas Easton,Michael D Badzioch,Alice S Whittemore,Ingrid Oakley-Girvan,Chih-Lin Hsieh,Latchezar Dimitrov,Jianfeng Xu,Janet L Stanford,Bo Johanneson,Kerry Deutsch,Laura McIntosh,Elaine A Ostrander,Kathleen E Wiley,Sarah D Isaacs,Patrick C Walsh,Stephen N Thibodeau,Shannon K McDonnell,Scott Hebbring,Daniel J Schaid,Ethan M Lange,Kathleen A Cooney,Teuvo L J Tammela,Johanna Schleutker,Thomas Paiss,Christiane Maier,Henrik ,Fredrik Wiklund,Monica Emanuelsson,William B Isaacs, ,

Previously, an analysis of 14 extended, high-risk Utah pedigrees localized in the chromosome 22q linkage region to 3.2 Mb at 22q12.3-13.1 (flanked on each side by three recombinants) contained 31 annotated genes. In this large, multi-centered, collaborative study, we performed statistical recombinant mapping in 54 pedigrees selected to be informative for recombinant mapping from nine member groups of the International Consortium for Prostate Cancer Genetics (ICPCG). These 54 pedigrees included the 14 extended pedigrees from Utah and 40 pedigrees from eight other ICPCG member groups. The additional 40 pedigrees were selected from a total pool of 1213 such that each pedigree was required to contain both at least four prostate cancer (PRCA) cases and exhibit evidence for linkage to the chromosome 22q region. The recombinant events in these 40 independent pedigrees confirmed the previously proposed region. Further, when all 54 pedigrees were considered, the three-recombinant consensus region was narrowed down by more than a megabase to 2.2 Mb at chromosome 22q12.3 flanked by D22S281 and D22S683. This narrower region eliminated 20 annotated genes from that previously proposed, leaving only 11 genes. This region at 22q12.3 is the most consistently identified and smallest linkage region for PRCA. This collaborative study by the ICPCG illustrates the value of consortium efforts and the continued utility of linkage analysis using informative pedigrees to localize genes for complex diseases.

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Publishing Authors By Initials

NJ Camp,LA Cannon-Albright,JM Farnham,AB Baffoe-Bonnie,A George,I Powell,JE Bailey-Wilson,JD Carpten,GG Giles,JL Hopper,G Severi,DR English,WD Foulkes,L Maehle,P Moller,R Eeles,D Easton,MD Badzioch,AS Whittemore,I Oakley-Girvan,CL Hsieh,L Dimitrov,J Xu,JL Stanford,B Johanneson,K Deutsch,L McIntosh,EA Ostrander,KE Wiley,SD Isaacs,PC Walsh,SN Thibodeau,SK McDonnell,S Hebbring,DJ Schaid,EM Lange,KA Cooney,TL Tammela,J Schleutker,T Paiss,C Maier,H ,F Wiklund,M Emanuelsson,WB Isaacs, ,

For similar health care economics and organizations: organizations: societies: societies, medical research abstracts see: health care economics and organizations: organizations: societies: societies, medical research

PUBMED ID PMID:

MEDLINE DATE:

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Human molecular genetics

VOLUME: 16

Page Numbers: 1271-8

Journal Abbreviation: Hum. Mol. Genet.

ISSN: 0964-6906

DAY: 3

MONTH: 05

YEAR: 2007

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9208958

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Keywords Mesh Terms:

KEYWORDS: Societies, Medical

MESH TERMS: genetics

Chemical & Substance for Abstract: Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.

AFFILIATION: University of Utah ICPCG Group and Division of Genetic Epidemiology, University of Utah School of Medicine, 391 Chipeta Way, Suite D, Salt Lake City, UT 84108, USA. nicola.camp@utah.edu

Country: England

AGENCY: United States NCI

GRANT: U01 CA89600

ACRONYM: CA

MEDLINETA: Hum Mol Genet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Compelling evidence for a prostate cancer gene at 22q123 by the International Consortium for Prostate Cancer Genetics Related Publications

• A cucurbit[6]uril analogue: host properties monitored by fluorescence spectroscopy.
• A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
• Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
• Anti-haemolytic action of viridans (alpha) variants of haemolytic streptococci.
• Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
• B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
• Chiral recognition inside a chiral cucurbituril.
• Combinatorial androgen receptor targeted therapy for prostate cancer.
• Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.
• Crohn's disease of the esophagus.
• Differential display reverse transcription-polymerase chain reaction to identify novel biomolecules in arthritis research.
• Fetal and neonatal hepatic tumors.
• Fetal and neonatal neuroblastoma: retrospective review of 271 cases.
• Gastro-jejunocolic and jejunocolic fistula.
• High fidelity kinetic self-sorting in multi-component systems based on guests with multiple binding epitopes.
• Insufficient rural doctors: Maslow's theory and the need for social accountability.
• Lethal and sublethal activities of imidacloprid contribute to control of adult Japanese beetle in blueberries.
• Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.
• Management of women at increased risk for hereditary breast cancer.
• Mitochondrial peroxiredoxins.
• Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
• Practical aspects of delivering hereditary cancer risk counseling.
• Preparation and properties of new derivatives of alloxan.
• Reconfigurable four-component molecular switch based on pH-controlled guest swapping.
• Some diseases of the blood.
• Substituent effects control the self-association of molecular clips in the crystalline state.
• The diagnosis and treatment of congestive heart failure.
• The effect of sodium withdrawal upon the body weight of normal young men.
• The identification and characterization of a monoclonal antibody to the vaccinia virus E3 protein.
• [Not Available.]